Disclosed are compounds that inhibit Lp-PLA2 activity, processes for their preparation, compositions containing them and their use in the treatment of diseases associated with the activity of Lp-PLA2, for example atherosclerosis, Alzheimer's disease, and/or diabetic macular edema.
-
(2012/06/30)
More Articles about upstream products of 1381791-45-2
Get Best Price for1381791-45-22-{[4-chloro-3-(trifluoromethyl)phenyl]oxy}-5-[({1-[(1-methyl-1H-pyrazol-4-yl)methyl]-2-oxo-1,2-dihydro-4-pyridinyl}oxy)methyl]benzonitrile